These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 18313522)

  • 1. Radiation retinopathy is treatable with anti-vascular endothelial growth factor bevacizumab (Avastin).
    Finger PT
    Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):974-7. PubMed ID: 18313522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-vascular endothelial growth factor bevacizumab (avastin) for radiation retinopathy.
    Finger PT; Chin K
    Arch Ophthalmol; 2007 Jun; 125(6):751-6. PubMed ID: 17562985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antivascular endothelial growth factor bevacizumab for radiation optic neuropathy: secondary to plaque radiotherapy.
    Finger PT; Chin KJ
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):789-98. PubMed ID: 21277107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of radiation maculopathy with intravitreal injection of bevacizumab (Avastin).
    Gupta A; Muecke JS
    Retina; 2008; 28(7):964-8. PubMed ID: 18698298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravitreal bevacizumab treatment for radiation macular edema after plaque radiotherapy for choroidal melanoma.
    Mason JO; Albert MA; Persaud TO; Vail RS
    Retina; 2007 Sep; 27(7):903-7. PubMed ID: 17891015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-VEGF bevacizumab (Avastin) for radiation optic neuropathy.
    Finger PT
    Am J Ophthalmol; 2007 Feb; 143(2):335-8. PubMed ID: 17258524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy.
    Avery RL; Pearlman J; Pieramici DJ; Rabena MD; Castellarin AA; Nasir MA; Giust MJ; Wendel R; Patel A
    Ophthalmology; 2006 Oct; 113(10):1695.e1-15. PubMed ID: 17011951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravitreal bevacizumab treatment of radiation maculopathy due to brachytherapy in choroidal melanoma.
    Ziemssen F; Voelker M; Altpeter E; Bartz-Schmidt KU; Gelisken F
    Acta Ophthalmol Scand; 2007 Aug; 85(5):579-80. PubMed ID: 17324216
    [No Abstract]   [Full Text] [Related]  

  • 9. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema.
    Kook D; Wolf A; Kreutzer T; Neubauer A; Strauss R; Ulbig M; Kampik A; Haritoglou C
    Retina; 2008 Oct; 28(8):1053-60. PubMed ID: 18779710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.
    Haritoglou C; Kook D; Neubauer A; Wolf A; Priglinger S; Strauss R; Gandorfer A; Ulbig M; Kampik A
    Retina; 2006; 26(9):999-1005. PubMed ID: 17151486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravitreal anti-VEGF bevacizumab (Avastin) for external beam related radiation retinopathy.
    Finger PT; Mukkamala SK
    Eur J Ophthalmol; 2011; 21(4):446-51. PubMed ID: 21218391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravitreal bevacizumab (avastin) treatment of retinal angiomatous proliferation.
    Ghazi NG; Knape RM; Kirk TQ; Tiedeman JS; Conway BP
    Retina; 2008 May; 28(5):689-95. PubMed ID: 18463511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study).
    Jorge R; Costa RA; Calucci D; Cintra LP; Scott IU
    Retina; 2006; 26(9):1006-13. PubMed ID: 17151487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. One-year outcomes of less frequent bevacizumab in age-related macular degeneration.
    Sonmez K; Sonmez PA; Ozkan SS; Atmaca LS
    Retina; 2011 Apr; 31(4):645-53. PubMed ID: 21358363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravitreal bevacizumab (avastin) for central and hemicentral retinal vein occlusions: IBeVO study.
    Costa RA; Jorge R; Calucci D; Melo LA; Cardillo JA; Scott IU
    Retina; 2007 Feb; 27(2):141-9. PubMed ID: 17290194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
    Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
    Retina; 2007; 27(4):432-8. PubMed ID: 17420694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
    Avery RL; Pieramici DJ; Rabena MD; Castellarin AA; Nasir MA; Giust MJ
    Ophthalmology; 2006 Mar; 113(3):363-372.e5. PubMed ID: 16458968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of intravitreal bevacizumab in treating postoperative pseudophakic cystoid macular edema.
    Spitzer MS; Ziemssen F; Yoeruek E; Petermeier K; Aisenbrey S; Szurman P
    J Cataract Refract Surg; 2008 Jan; 34(1):70-5. PubMed ID: 18165084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
    Rich RM; Rosenfeld PJ; Puliafito CA; Dubovy SR; Davis JL; Flynn HW; Gonzalez S; Feuer WJ; Lin RC; Lalwani GA; Nguyen JK; Kumar G
    Retina; 2006; 26(5):495-511. PubMed ID: 16770255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up.
    Arevalo JF; Fromow-Guerra J; Quiroz-Mercado H; Sanchez JG; Wu L; Maia M; Berrocal MH; Solis-Vivanco A; Farah ME;
    Ophthalmology; 2007 Apr; 114(4):743-50. PubMed ID: 17398322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.